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Abstract
THE ROLE OF NITRIC OXIDE SCAVENGING IN HEMOGLOBIN-BASED
OXYGEN CARRIER INDUCED HYPERTENSION: SYSTEMIC AND
MICROVASCULAR EFFECTS
By Alan R. Ottarson, MS
A thesis submitted in partial fulfilment of the requirements for the degree of
Master of Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2014
Director: Roland N. Pittman, PhD, Professor, Department of Physiology &
Biophysics

The purpose of this study was to identify the effects of a hemoglobin-based
oxygen

carrier,

HBOC-201,

on

the

cardiovascular

system.

Systemic

cardiovascular parameters of mean arterial pressure (MAP), pulse pressure,
heart rate, and oxygen saturation, as well as vascular resistance, were
examined. A murine model of the cardiovascular system and microvasculature
was employed. Sprague-Dawley rats (male; 230-530g; N = 13) were
anaesthetised and surgically prepared for intravital microscopy of the
spinotrapezius muscle. Increasing doses of HBOC-201 (2 mg/kg, 22 mg/kg, 230
mg/kg, and 780 mg/kg) and an iso-oncotic volume control were administered to
assess for a dose-response relationship. MAP displayed a significant increase
from baseline for both treatment groups, with no significant difference between
the two. Arteriolar diameter displayed no changes from baseline, or between
treatment groups or across doses. Based on these results, the noted changes in
MAP were due to hypervolemia, and not a property of HBOC-201, itself.
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Introduction
Trauma and associated hemorrhage often result in the development of
hypovolemic shock and subsequent tissue and cell death due to ischemia. Many
patients suffering from traumatic injury often require massive blood product
transfusion in order to maintain blood pressure, tissue oxygenation, and normal
coagulation status(Hess, Holcomb, & Hoyt, 2006). This massive transfusion is
often defined as 10 or more units of packed red blood cells (PRBCs) in a 24-hour
period, worsening the prognosis for these patients and increasing mortality.
Currently, blood product transfusion is the standard of care for hemorrhaging
trauma patients, along with crystalloid fluid administration to restore volume
quickly(Como, Dutton, Scalea, Edelman, & Hess, 2004; Davis, Johannigman, &
Pritts, 2012; Geeraedts, Kaasjager, van Vugt, & Frolke, 2009; Harris, Thomas, &
Brohi, 2012; Holcomb et al., 2008). Unfortunately, many areas of the world do not
have ready access to blood products, and those that do face the challenge of
finding enough donors to meet the demand. Without an adequate and consistent
source of human blood products, the goal of maintaining tissue perfusion may
often be unobtainable.
Efficient transport of respiratory gases is imperative for the maintenance of
tissue perfusion. As stated earlier, large-volume crystalloid fluid administration is
used to restore volume quickly. However, it comes at a price. Without
administration of additional oxygen-carrying red blood cells (RBCs), the patient
will develop a condition termed isovolemic anemia. This occurs in the presence
of

!

adequate

blood

volume,

but

1!

low

or

inadequate

hemoglobin

!
concentration(Gutierrez, Reines, & Wulf-Gutierrez, 2004). This condition has
been documented as normal for certain patient populations (e.g.: renal failure),
and benign in healthy volunteers, but does come with certain physiological
characteristics. In a study of healthy volunteers subjected to acute isovolemic
hemodilution to a hemoglobin level of 5 g/dL (normal range = 12-17 g/dL),
subjects demonstrated significant increases in heart rate, stroke volume, and
!"

cardiac index (!" = !"# =

!"∗!"
!"#

), though hypoxia was absent(Weiskopf et al.,

1998). While not detrimental to healthy individuals, these physiological changes
almost certainly impact the outcome of a patient experiencing hemorrhagic
shock.
The problem of supply versus demand has plagued blood product therapy
since its beginning, and with growing populations, has only gotten worse. Many
research groups have attempted to solve this issue by developing blood product
replacements such as artificial oxygen carriers, plasma and platelets. Many of
these products have extended shelf lives, wide environmental ranges, and can
be mass-produced(Greenburg & Kim, 2004). These attributes make blood
product replacements a desirable area of focus, though many issues have been
found with those currently in development. These side effects, some of which will
be discussed in detail later, serve as a roadblock for the industry, preventing
many products from ever reaching the market. It is only through understanding
the mechanisms behind such effects that safe and reliable replacements can be
created. The main area of interest for this project involves artificial red blood cell
replacements, otherwise known as hemoglobin-based oxygen carriers (HBOCs).
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Hemoglobin-based oxygen carriers are natural or synthetic red blood cell
substitutes that were originally designed to enhance the transport of respiratory
gases in patients suffering from hemorrhagic shock or general hypovolemia.
Ideally, these solutions are shelf-stable and readily exchange oxygen with the
surrounding tissue, acting as a suitable transfusion in lieu of whole blood or
packed red blood cells(Hughes et al., 1996). Their designs are generally
proprietary, but often include some form of crosslinking or polymerization that
results in differing sizes of “particles” depending on the manufacturer (Greenburg
& Kim, 2004; Sakai et al., 2000; Silverman, Weiskopf, & Planning Committee and
the Speakers, 2009; Tsai et al., 2006).
In order to understand how HBOCs affect blood pressure, it is important to
understand the mechanisms by which blood pressure is normally regulated.
There are many systems and pathways that interact with each other and keep
each other in check to achieve homeostasis. Of particular interest in this
investigation, nitric oxide (NO) is a prime example of a regulatory molecule that
produces

vasodilation.

Likewise,

endogenous

catecholamines

produce

vasoconstriction, which leads to an increase in blood pressure. It is this constant
balancing act between hypotensive and hypertensive mechanisms that goes
awry in the presence of an outside force, such as disease, trauma, or
pharmacotherapeutics.
Nitric oxide (NO) is an important gaseous, free radical molecule that is
involved in many processes as a messenger(Lowenstein, Dinerman, & Snyder,
1994). NO is synthesised endogenously by nitric oxide synthase (NOS), which is
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found in the endothelium (eNOS), neuronal system (nNOS), and as an immune
system inducible isoform (iNOS). Each of these is a known constituent of their
respective tissues, and has the ability to catalyze a number of reactions that
generate NO from its precursor, L-arginine(Knowles & Moncada, 1994). Of
particular importance to the topic at hand is eNOS, which as stated before, is
found in vascular endothelial cells.
The synthesis of NO in the vascular system helps to regulate blood
pressure by direct stimulation of vascular smooth muscle adjacent to the
endothelium(Rees, Palmer, & Moncada, 1989; Umans & Levi, 1995). NO has an
affinity for the iron molecules of endogenous heme groups that is much higher
than that of oxygen and respiratory gases. This affinity leads to NO binding of
heme on guanylate cyclase, activating the enzyme that leads to production of
cyclic

guanosine

monophosphate

(cGMP)

and

subsequent

muscle

relaxation(Ignarro, 1991; Lowenstein et al., 1994). Though direct muscle
relaxation is a significant mechanism in the role of NO in vascular tone, it is not
the only one.
Nitric oxide acts centrally on the sympathetic nervous system, as well as
peripherally by upregulation of endothelin (ET) receptors. Direct injection of NO
into the central nervous system has demonstrated a small, but significant
vasoconstriction response that can be terminated by transection of the spinal
cord (Togashi et al., 1992). Similarly, NO is thought to play a role in regulation of
the potent vasoactive peptide, ET. This 21-amino acid polypeptide binds to
several receptors, and derives its vasoconstrictor actions from the ET-A receptor
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subtype. Binding of endothelin to ET-A directly stimulates smooth muscle
contraction, resulting in an increase in blood pressure (Redmond, Cahill, Hodges,
Zhang, & Sitzmann, 1996; Rubanyi & Polokoff, 1994).
Cell free hemoglobin has the ability to scavenge nitric oxide from the blood
and chemically alter their forms (methemoglobin and nitrate [NO3-], respectively)
(Doherty et al., 1998; Huang et al., 2005; Olson et al., 2004; Smani, Fifre,
Labrude, Vigneron, & Faivre, 2007; Tsai et al., 2006; Yu et al., 2010). This
scavenging and subsequent loss of the vasoregulatory agent, NO, leads to
marked increases in blood pressure, one of the side effects that has kept HBOCs
from being introduced to the market(Alayash, 1999; Angele, Schneider, &
Chaudry, 2008; Fitzpatrick, Savage, Kerby, Clouse, & Kashyap, 2004; Olson et
al., 2004; Tsai et al., 2006; Yu et al., 2010). In the case of major traumatic
hemorrhage, it has been found prudent to titrate volume replacements to a
systolic blood pressure of 90-100 mmHg in order to decrease instances of
bleeding while maintaining perfusion. Systolic blood pressures of greater than
100 mmHg are detrimental to hemostasis, and do not enhance vital perfusion
already taking place. Hence, HBOC-induced blood pressure changes currently
make this an unsuitable treatment for this patient population (Davis et al., 2012;
Harris et al., 2012; Hess et al., 2006; Moore, Johnson, Cheng, Masuno, &
Banerjee, 2005).
Given the different sizes and compositions of each HBOC, it is currently
unknown as to the full extent of these differences in terms of physiological effects
and pharmacokinetics. In 2000, Sakai et al demonstrated that HBOC particle size
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affected arterial constriction and hypertension, while a study by Tsai et al (2006)
showed inconsistency in hypertensive effects based on HBOC molecular
configuration (Sakai et al., 2000; Tsai et al., 2006). Therefore, it is not
unreasonable to conclude that size affects the distribution of HBOCs, possibly
affecting their mechanism of action.
The specific HBOC of interest in this study is a bovine hemoglobin
glutamer-250 known as HBOC-201. It is manufactured by the Biopure
Corporation, now known as OPK Biotech, and consists of particles that weigh, on
average, 250 kDA, or approximately four times the molecular weight of a
standard endogenous hemoglobin tetramer. Its oxygen affinity (P50) is
approximately 36 mmHg, while that of endogenous RBC hemoglobin is 13
mmHg(Dube, Vranckx, & Greenburg, 2008; Standl et al., 2003). Oxygen affinity
has a negative correlation with percent saturation. Therefore, this cross-linked
bovine hemoglobin has a much lower affinity for oxygen than its endogenous
counterpart.
It is our hypothesis that administration of a HBOC will directly affect blood
pressure, vascular resistance, and other cardiovascular parameters. Specifically,
we predict there will be an increase in mean arterial pressure (MAP), systemic
vascular resistance (decreased arteriolar diameter), and possibly heart rate. We
also hypothesize that oxygen saturation will decrease, as evidenced by past
studies on pulse oximetry and HBOC administration (Hughes et al., 1996). These
parameters will display responses directly proportional to the dose of HBOC
administered, producing a standard dose-response curve.
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Methods
Subjects and Instrumentation
A murine model was employed for this investigation, with male rats (spp.
Rattus norvegicus; Sprague-Dawley) weighing 200-500 g being sedated via initial
intraperitoneal (IP) injection of ketamine (75 mg/kg) and acepromazine (2.5
mg/kg). After successful sedation, the femoral triangles, abdomen, and ventral
neck were shaved and cleaned with ethyl alcohol. The subjects were placed on a
normothermic (37˚C), heated conduction pad for facilitation of electrocautery. A
patent airway was established via surgical tracheotomy and maintained for the
duration of the experiment.
After assurance of adequate ventilation, the right or left femoral vein was
surgically isolated and cannulated for access to the central venous circulation
and administration of additional intravenous (IV) anesthesia. Alfaxan (alfaxalone
acetate; Jurox, Inc., Kansas City, MO) was administered at a rate of 0.1
mg/kg/min to maintain general anaesthesia. A toe pinch was performed at 15minute intervals to assess for the effectiveness of anesthesia, and levels were
adjusted appropriately. The right or left femoral artery was then surgically
isolated and cannulated for hemodynamic monitoring, including mean arterial
pressure (MAP), pulse pressure, and heart rate (HR). A second central venous
line was inserted into the right or left internal jugular vein as a route for
administration of test solutions.
Surgical exteriorization and preparation of a unilateral section of
spinotrapezius muscle was performed in order to isolate a segment of skeletal
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muscle vasculature. (Gray, 1973) The isolated muscle was reflected and
displayed over a heated (37˚C) Lexan polycarbonate (SABIC, Riyadh, Saudi
Arabia) platform for viewing by intravital microscopy. The muscle was kept moist
by the addition of normal saline and a Krehalon covering, which was also used to
prevent atmospheric interference. At the conclusion of each experiment, the rats
were euthanized by IV administration of 0.4 mL/kg Euthasol (pentobarbital 390
mg/mL, phenytoin 50 mg/mL; Delmarva Laboratories, Midlothian, VA). All
procedures and treatments were approved as part of this protocol by the VCU
Institutional Animal Care and Use Committee.

Physiological Monitoring
Arterial blood pressure and heart rate were continuously measured after
initial surgical instrumentation by a pressure transducer attached to the IV
cannula in the carotid artery. Data for hemodynamic status were recorded using
integrated software (BIOPAC Systems, Inc., Goleta, CA). Body temperature was
continuously monitored by use of a rectal thermometer, and non-invasive pulse
oximetry (Nonin PulseSense™, Nonin Medical, Inc., Plymouth, MN) provided
data on SpO2 and HR.

Treatment
Rats were divided into two study groups: HBOC-201 (Hemopure® bovine
hemoglobin

glutamer-250,

Biopure®

Corporation,

Cambridge,

MA)

IV

administration and Human Serum Albumin (Albumin, Human 25%, ZLB Behring
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AG, Berne Switzerland) volume control IV administration. A top-load infusion was
utilized for this study. As described in previous studies, a dose-response effect
was sought by sequential administration of escalating doses of HBOC-201 and
HSA control. The stock solution of 25% HSA was diluted to an iso-oncotic
concentration of 5.9% (Mongan et al., 2009). Doses for HBOC-201 IV
administration included Dose 1, 2 mg/kg; Dose 2, 22 mg/kg; Dose 3, 230 mg/kg;
and Dose 4, 780 mg/kg. HSA control doses were administered to correspond
with infused volumes of HBOC-201, and included Dose 1, 0.4 mL/kg; Dose 2, 0.4
mL/kg; Dose 3, 3.8 mL/kg; and Dose 4, 13.1 mL/kg. Due to the inherent and
relatively low blood volume of rats, the volumes of administered doses had to be
adjusted accordingly by concentration to maintain a reasonable infusion volume.
Therefore, the highest dose (13.1 mL/kg) was reduced to 6.55 mL/kg, and an
undiluted stock solution of HBOC 201 was used. The subsequent control was
also lowered to 6.55 mL/kg.
Rats were allowed an equilibration period of approximately 15 minutes
prior to obtaining the baseline measurements and administering the first infusion.
Each dose was administered at a rate of 1 mL/min, and a 10-minute interval
between doses was observed.

Microscopy
In vivo microcirculatory studies were performed by intravital microscopy
(Figure 1) of the skeletal muscle vasculature using an Axioimager A1m
microscope (Carl Zeiss Microscopy, LLC, Oberkochen, Germany). Each rat was
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Figure 1. Intravital microscope diagram. Note: PMT was not used in this series of
experiments, but remained as a part of the microscope setup. (Credit:
Aleksander Golub)
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Figure 2. Thermostatic platform. Shown with temperature regulator and pedestal
for muscle preparation. (Credit for muscle prep picture: Aleksander Golub)
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placed on its side on a thermostatic platform with a unilateral section of
exteriorised and isolated spinotrapezius muscle reflected onto a pedestal (Figure
2) (Golub & Pittman, 2003). The muscle preparation was stretched and secured
via silk surgical suture and covered with a polyvinylidene chloride film (Krehalon,
Kureha America, Inc., New York, NY). The film was secured to the pedestal via a
neoprene ring and pushpins.
A Krehalon “bag” and modified hypodermic needle were secured to the
objective lens via wrapping with electrical tape. The needle served to provide an
inlet by which an air compressor could keep the air between the bag and
objective lens at a constant pressure (8-12 mmHg), and electrical tape prevented
any unwanted air escape. A small amount of transparent lubricant was applied to
the Krehalon cover of the muscle preparation to reduce friction between it and
the objective lens “bag”.
Randomly selected, isolated skeletal muscle arterioles with a diameter
range of 30-80 µm were identified as sites for measurement during treatment,
with three such sites identified for each rat. Baseline measurements were
obtained after a short equilibration period, and included arteriolar diameter, MAP,
pulse pressure, HR, and pulse oximetry (SpO2). After administration of the
treatment or control solutions, measurements were reobtained.

Statistical Analysis
Unless otherwise noted, all data are presented as mean ± standard error
of the mean (SEM). An analysis of variance and F test were performed to detect
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differences within groups and across doses, while a Tukey HSD test was utilised
to determine significant differences among specific points.
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Results
Systemic Parameters
Mean Arterial Pressure
Figures 3 and 4 display the relationship between dose and MAP for the two
treatment groups (HBOC-201 and 5.9% HSA). Tables 1 and 2 display a
summary of the data and statistical analysis for all parameters. Overall (Figure
5), there was a significant increase in MAP (p < 0.05) from baseline (102.70 ±
2.32 mmHg, N = 13) to the two highest doses (3.8 mL/kg: 124.07 ± 3.18 mmHg,
N = 13; 6.55 mL/kg: 121.69 ± 2.59 mmHg, N = 13), but there was no difference
between the two lowest doses or between the two highest doses (Table 2). For
specific comparisons, the 3.8 mL/kg (HBOC-201: 130.84 ± 3.77 mmHg, N = 7;
5.9% HSA: 116.17 ± 3.07 mmHg, N = 6) and 6.55 mL/kg (HBOC-201: 125.87 ±
2.70 mmHg, N = 7; 5.9% HSA: 116.82 ± 3.97 mmHg, N = 6) doses of both
treatment solutions were significantly different (p < 0.05) from the other groups,
though not from each other.

Pulse Pressure
The relationship between pulse pressure and dose is displayed in Figure
6. Summary statistics for pulse pressure can be found in Tables 1 and 2. No
significant differences were found overall from baseline (48.16 ± 2.76 mmHg, N =
13) or between the two treatment groups and across doses. Likewise, when
considering the effects of treatment and dose together, no significant differences
were found.
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Mean Arterial Pressure
140.00
Mean Arterial Pressure (mmHg)

*
*

130.00
*

120.00

*

110.00
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HBOC 201

100.00
90.00
80.00
Baseline

0.4

0.4

3.8

6.55

Dose (mL/kg)

Figure 3. Dose-Response Bar Graph (MAP). HBOC-201 (N = 7) doses converted
to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N = 6).
Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); Dose 2,
22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg (~300
µM). * denotes statistically significant difference (p < 0.05) from baseline.
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Mean Arterial Pressure
Mean Arterial Pressure (mmHg)
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*
*

130.00
120.00
*

110.00

*
Control
HBOC 201

100.00
90.00
80.00
Baseline

0.4

0.4

3.8

6.55

Dose (mL/kg)

Figure 4. Dose-Response Line Graph (MAP). HBOC-201 (N = 7) doses
converted to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N =
6). Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM);
Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg
(~300 µM). * denotes statistically significant difference (p < 0.05) from baseline.
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Figure 5. Combined Treatment Dose-Response (MAP). This figure represents
the total mean (HBOC-201 and 5.9% HSA) change from baseline across doses.
HBOC-201 (N = 7) doses converted to mL/kg to correspond to 5.9% HSA isooncotic volume control (N = 6). Concentrations of HBOC-201 were as follows:
Dose 1, 2 mg/kg (~1 µM); Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100
µM); Dose 4, 780 mg/kg (~300 µM). * denotes statistically significant difference
(p < 0.05) from baseline.
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Table 1. Summary statistics for systemic parameters by treatment group. HBOC-201 (N = 7) doses converted to mL/kg
to correspond to 5.9% HSA iso-oncotic volume control (N = 6). Concentrations of HBOC-201 were as follows: Dose 1, 2
mg/kg (~1 µM); Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg (~300 µM). SpO2 =
oxygen saturation
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Table 2. Summary statistics for systemic parameters not differentiated by treatment group. HBOC-201 (N =
7) doses converted to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N = 6). Concentrations
of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg
(~100 µM); Dose 4, 780 mg/kg (~300 µM). SpO2 = oxygen saturation
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Pulse Pressure
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Figure 6. Dose-Response Graph (Pulse Pressure). HBOC-201 (N = 7) doses
converted to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N =
6). Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM);
Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg
(~300 µM). No statistically significant changes were noted in any comparisons,
however, a slight upward trend can be seen in the graph.
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Heart Rate
The relationship between heart rate and dose is displayed in Figure 7.
Data pertaining to heart rate can be found in Tables 1 and 2. No significant
differences from the baseline (312.69 ± 13.31, N = 13) were found between the
two treatment groups, or across doses. Likewise, when considering the effects of
treatment and dose together, no significant differences were found.

Pulse Oximetry
The

dose-response

relationship

between

the

pulse

oximetry

measurements and treatment is displayed in Figure 8. Tables 1 and 2 display the
summary statistics for oxygen saturation (pulse oximetry). Overall, only one
significant difference was noted among the doses, with the highest dose (6.55
mL/kg: 86.31 ± 1.30, N = 13, p < 0.05) resulting in a lower pulse oximetry reading
than the other doses. Across treatment groups and doses, the 6.55 mL/kg
HBOC-201 dose (83.00 ± 1.35, N = 7, p < 0.05) produced significantly lower
pulse oximetry readings than all other doses, with the exceptions of the 3.8
mL/kg control (89.33 ± 1.28, N = 6, p = 0.1027) and HBOC-201 (87.57 ± 1.81, N
= 7, p = 0.4322) doses. No other significant differences were observed.
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Figure 7. Dose-Response Graph (Heart Rate). HBOC-201 (N = 7) doses
converted to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N =
6). Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM);
Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg
(~300 µM). No statistically significant changes were noted in any comparisons,
however, as with pulse pressure (Figure 6), a slight upward trend can be seen in
the graph.
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Figure 8. Dose-Response Graph (Oxygen Saturation). HBOC-201 (N = 7) doses
converted to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N =
6). Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM);
Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg
(~300 µM). * denotes statistically significant difference (p < 0.05) from baseline. Δ
denotes statistically significant difference (p < 0.05) from control at the current
dose.
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Microvascular Parameters
Arteriolar Diameter
Due to the wide range of vessel sizes (30-80 µm), data for arteriolar
diameter changes are reported using percent (%) change from baseline (Figure
9). A positive change indicates an increase in arteriolar diameter, whereas a
negative change indicates a decrease. Arterioles were divided into three groups,
those most distal (HBOC-201: 4.40 ± 1.29, N = 12; 5.9% HSA: 1.89 ± 2.00, N =
16), proximal (HBOC-201: 4.77 ± 2.81, N = 12; 5.9% HSA: 5.86 ± 2.44, N = 16),
and a distance between the two extremes (HBOC-201: 7.35 ± 2.51, N = 12; 5.9%
HSA: -2.04 ± 1.75, N = 13), with each vessel being compared to others in its
group. Diameter changes were also compared across location groups and doses,
as well as overall treatment by itself (HBOC-201 v. 5.9% HSA). No significant
differences in arteriolar diameter were noted across any groups.
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Arteriolar Diameter Change
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Figure 9. Dose Response Graph (Vascular Resistance). Results expressed as %
change due to wide variation in vessel sizes. HBOC-201 (N = 9) doses converted
to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N = 11).
Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); Dose 2,
22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg (~300
µM). Three vessel sites were chosen in each muscle preparation, with N = 4
(5.9% HSA) and N = 3 (HBOC-201). No statistically significant differences were
noted from baseline, or between treatment groups.
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Discussion
The results of this study suggest a plateau in the effect of HBOC-201 in
regard to dose-response. As the dose of HBOC-201 increased, the MAP also
increased, but only to a certain point. This serves to demonstrate a sigmoid curve
rather than a direct linear relationship between dose and cardiovascular
response. While very little statistical significance was found, there is an obvious
trend in the data for MAP that suggests a closer association between dose and
pressure. Results for the second lowest dose of HBOC-201, while not statistically
significant, appears to produce a higher MAP than the HSA control. This is
consistent with recent, similar studies that suggest no significant difference in
MAP between the control and HBOC treatments (Song et al., 2013; Song,
Nugent, Moon-Massat, & Pittman, 2014).
No statistically significant differences were found with either the pulse
pressure or heart rate parameters; however, slight trends were noticed in the
graphed data. A slight and gradual increase in both parameters can be seen,
though both the HSA control and HBOC-201 groups tended to mimic each other
in magnitude of response. One point of interest is the fact that the average heart
rate appeared consistently higher in the HSA control group than in the HBOC201 group, though not significantly so.
Pulse oximetry was the only other parameter to show a significant change.
The HSA control appeared to stay fairly consistent throughout the experiment
with regard to SpO2, while the HBOC-201 treatment group showed a dramatic
and obvious decrease after the two highest doses. These data are consistent
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with previous studies showing a decrease in oxygen saturation after
administration of a cell-free HBOC solution(Hughes et al., 1996). The artificially
decreased affinity for oxygen of HBOC-201 appears to be the cause of lower
pulse oximetry readings, however, previous studies have shown a much lower
magnitude of change compared to the results described here. The use of a
murine model may have contributed to the increased magnitude of change seen
in this study, but further research will have to be performed in order to determine
this effect.
Interestingly, as stated before, there was an observed lack of arteriolar
response to HBOC-201 administration. Coupled with the lack of change in heart
rate, it is curious to note the much more obvious increase in MAP. Control of
MAP can be reduced to three main components: cardiac output, systemic
vascular resistance (SVR), and blood volume. This model attempts to control for,
and measure, each component of this system in some way. Cardiac output can
be determined by multiplying heart rate and stroke volume, of which we directly
measured heart rate in two ways (non-invasive pulse oximetry and arterial
catheter placement). Systemic vascular resistance was directly measured by
intravital microscopy of skeletal muscle arterioles, which leads to indirect
calculation of regional blood flow, even though flow was not directly measured.
Finally, blood volume changes were accounted for by administration of a control
solution of iso-oncotic 5.9% human serum albumin to prevent fluid shift into or
out of the interstitial space after administration. The 5.9% HSA was also used as
the diluent for varying the HBOC-201 concentrations.
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Based on the results of this study, and the lack of change in several
parameters that directly affected blood pressure, we are led to infer that an
increase in stroke volume may have occurred that resulted in an overall increase
in MAP. Cardiac output was not directly measured in this set of experiments,
though the placement of a flow probe or thermodilution catheter may provide
better insight into the cause of the blood pressure increase(Phillips et al., 2012;
Swan et al., 1970).
As originally stated, several doses of HBOC-201 were used, representing
2, 22, 230, and 780 mg/kg. While the doses were converted to a consistent
volume relative to the HSA control solution, one variable remained unaccounted
for. One central venous catheter was used for administration of each dose, with
each syringe being replaced by the next with a higher dose. Unfortunately, the
dead space in the catheter and hub was not insignificant, accounting for
approximately 0.6 mL of volume. The average volume of the first infusion was
0.14 mL, and the average total volume infused was 3.95 mL. Inadvertent and
unavoidable inter-infusion doses of 0.6 mL occurred with each syringe change,
adding a total of 1.2 mL to the total dose. These inter-infusion doses were
consistent across all subjects, occurring with approximately the same volume
and time between each syringe change. Unfortunately, it is currently unknown if
or how these extra boluses affected the above-described parameters.
In brief, the results of this study demonstrate that HBOC-201 does not
have any more effect on several cardiovascular parameters than an iso-oncotic
volume control. This is in direct contrast with previous studies using many
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different models, (Caron, Malfatti, Aguejouf, Faivre-Fiorina, & Menu, 2001;
Freilich et al., 2009; Vogel, Dennis, Cassidy, Apstein, & Valeri, 1986; Winslow et
al., 1998; Winslow, 2004) though compared to systemic studies, few
microvascular studies have been performed to shed light on this issue. These
results do correspond, however, to similar, recently published studies on rat
mesentery and skeletal muscle microvascular effects(Song et al., 2013; Song et
al., 2014). The lack of difference between the HBOC-201 and iso-oncotic volume
control seems to point to volume expansion as the main culprit behind the
hypertensive effect, and not a property of HBOC-201, itself. As the NO
scavenging hypothesis relies on this specific property of HBOC-201, it is clear
that this effect is minimal at best, if present at all. Several past studies utilized
other volume controls, such as isotonic or hypertonic crystalloids and colloids,
similar to those used in clinical practice. This, however, allows for much broader
variation in fluid dynamics in the body, as these fluids may rapidly leave the
vascular space, which an endogenous iso-oncotic fluid would likely avoid
(Mazzoni, Borgstrom, Arfors, & Intaglietta, 1988; Quinlan, Martin, & Evans,
2005).
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Table 3. Summary statistics for vascular resistance. HBOC-201 (N = 9) doses converted to mL/kg to correspond to 5.9% HSA iso-oncotic
volume control (N = 11). Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); Dose 2, 22 mg/kg (~10 µM); Dose 3, 230
mg/kg (~100 µM); Dose 4, 780 mg/kg (~300 µM). Three vessel sites were chosen in each muscle preparation, with N = 4 (5.9% HSA) and N
= 3 (HBOC-201). No statistically significant differences were noted from baseline, or between treatment groups.
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